Elevance Health, Inc. $ELV Stock Bought by Chicago Partners Investment Group LLC

Key Points

• Chicago Partners Investment Group increased its Elevance Health stake by 119.9% in the third quarter, to 5,377 shares valued at about $2.37 million.
• Elevance reported quarterly EPS of $6.99, beating the $4.71 consensus, and revenue of $50.44 billion, also above estimates. The company declared a $1.72 quarterly dividend, equivalent to a 1.6% yield.
• Analysts’ average rating is “Moderate Buy,” with a $456.48 average price target. Earnings estimates were mixed, with some upward revisions and cuts to forecasts for several future quarters.

Chicago Partners Investment Group LLC raised its position in shares of Elevance Health, Inc. (NYSE:ELV - Free Report) by 119.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,377 shares of the company's stock after acquiring an additional 2,932 shares during the period. Chicago Partners Investment Group LLC's holdings in Elevance Health were worth $2,366,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of ELV. Field & Main Bank boosted its position in Elevance Health by 1.3% during the 2nd quarter. Field & Main Bank now owns 1,883 shares of the company's stock valued at $728,000 after acquiring an additional 25 shares in the last quarter. Simplicity Wealth LLC raised its holdings in Elevance Health by 1.3% in the 3rd quarter. Simplicity Wealth LLC now owns 1,939 shares of the company's stock valued at $754,000 after acquiring an additional 25 shares during the last quarter. Tranquilli Financial Advisor LLC raised its position in Elevance Health by 1.3% in the second quarter. Tranquilli Financial Advisor LLC now owns 2,081 shares of the company's stock valued at $805,000 after purchasing an additional 26 shares during the period. Mather Group LLC. grew its holdings in shares of Elevance Health by 3.5% in the third quarter. Mather Group LLC. now owns 766 shares of the company's stock valued at $298,000 after purchasing an additional 26 shares in the last quarter. Finally, 55 North Private Wealth LLC increased its holdings in Elevance Health by 4.5% in the third quarter. 55 North Private Wealth LLC now owns 598 shares of the company's stock valued at $233,000 after buying an additional 26 shares during the last quarter. Institutional investors own 89.24% of the company's stock.

More Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $29.02 from $27.06, and lifted forecasts for Q1 2027 and Q1 2028 to $11.73 and $12.61, respectively. An additional analyst also raised its Q2 EPS estimate, though the report did not provide the revised figure. Q2 EPS Estimate for Elevance Health Lifted by Analyst
• Neutral Sentiment: EVP Ratnakar Lavu sold 1,300 shares for $572,000, an 8.05% reduction in his holdings. He still directly owned 14,849 shares after the transaction, making the sale a limited insider-sentiment signal. SEC insider transaction filing
• Neutral Sentiment: A separate article considers what would need to be true for Elevance to be an attractive stock purchase, but the supplied article information does not state its conclusion. What Needs To Be True To Buy Elevance Health Stock?
• Negative Sentiment: Zacks Research lowered estimates for Q4 2026 EPS to $2.00 from $2.43, Q3 2027 to $6.01 from $6.70, and Q3 2028 to $7.09 from $7.75. These cuts temper the positive revisions and point to a less favorable outlook for some future quarters.

Elevance Health Stock Performance

Shares of NYSE:ELV traded down $5.83 during mid-day trading on Friday, reaching $426.17. The company had a trading volume of 1,443,875 shares, compared to its average volume of 1,442,885. Elevance Health, Inc. has a one year low of $274.84 and a one year high of $450.69. The company's 50-day moving average price is $412.92 and its 200-day moving average price is $373.58. The company has a current ratio of 1.47, a quick ratio of 1.47 and a debt-to-equity ratio of 0.68. The firm has a market cap of $92.08 billion, a price-to-earnings ratio of 18.17, a PEG ratio of 1.97 and a beta of 0.63.

Elevance Health (NYSE:ELV - Get Free Report) last issued its quarterly earnings results on Wednesday, October 21st. The company reported $6.99 EPS for the quarter, topping analysts' consensus estimates of $4.71 by $2.28. The firm had revenue of $50.44 billion for the quarter, compared to analyst estimates of $49.28 billion. Elevance Health had a net margin of 2.55% and a return on equity of 14.97%. The business's revenue for the quarter was up .7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $6.03 EPS. As a group, equities research analysts anticipate that Elevance Health, Inc. will post 29.16 EPS for the current fiscal year.

Elevance Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 18th. Shareholders of record on Friday, December 4th will be paid a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.6%. The ex-dividend date of this dividend is Friday, December 4th. Elevance Health's dividend payout ratio (DPR) is presently 29.34%.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. The Goldman Sachs Group reiterated a "neutral" rating and set a $451.00 price target on shares of Elevance Health in a research report on Friday, October 23rd. Wells Fargo & Company upped their price target on shares of Elevance Health from $473.00 to $492.00 and gave the company an "overweight" rating in a report on Tuesday, October 27th. Guggenheim upped their target price on Elevance Health from $460.00 to $485.00 and gave the stock a "buy" rating in a research report on Thursday, October 22nd. Morgan Stanley raised their price objective on shares of Elevance Health from $404.00 to $449.00 and gave the company an "equal weight" rating in a research report on Thursday, October 22nd. Finally, Mizuho set a $490.00 target price on Elevance Health in a research report on Friday, October 23rd. Fifteen equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $456.48.

Insiders Place Their Bets

In related news, EVP Ratnakar Lavu sold 1,300 shares of the stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $440.00, for a total value of $572,000.00. Following the transaction, the executive vice president owned 14,849 shares in the company, valued at approximately $6,533,560. This represents a 8.05% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Mark Kaye sold 10,584 shares of the stock in a transaction that occurred on Thursday, October 22nd. The stock was sold at an average price of $440.13, for a total value of $4,658,335.92. Following the transaction, the chief financial officer owned 19,919 shares in the company, valued at $8,766,949.47. This represents a 34.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.34% of the company's stock.

About Elevance Health

Elevance Health, Inc is a U.S. health benefits and services company. Formerly known as Anthem, Inc, it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans.

The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.

Elevance Health operates primarily in the United States, with health plans serving members across multiple states and access to broader provider networks through its Blue Cross Blue Shield affiliations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.